Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Rating Increased to Buy at Societe Generale

Societe Generale upgraded shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) from a hold rating to a buy rating in a research report released on Friday, Marketbeat Ratings reports.

Other equities research analysts have also recently issued reports about the company. Citigroup assumed coverage on Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, August 1st. They issued a neutral rating for the company. StockNews.com lowered Fresenius Medical Care AG & Co. KGaA from a strong-buy rating to a hold rating in a report on Friday, November 3rd. Truist Financial cut their price objective on Fresenius Medical Care AG & Co. KGaA from $28.00 to $24.00 and set a hold rating on the stock in a report on Wednesday, October 11th. Morgan Stanley raised their target price on Fresenius Medical Care AG & Co. KGaA to €40.50 ($44.51) in a report on Wednesday, August 16th. Finally, UBS Group raised Fresenius Medical Care AG & Co. KGaA from a sell rating to a neutral rating in a report on Wednesday, September 13th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of Hold and an average price target of $25.40.

Fresenius Medical Care AG & Co. KGaA Trading Down 0.6 %

Shares of NYSE FMS opened at $19.61 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.37 and a quick ratio of 1.02. The stock has a market capitalization of $11.51 billion, a P/E ratio of 23.91 and a beta of 1.04. Fresenius Medical Care AG & Co. KGaA has a 1-year low of $14.82 and a 1-year high of $27.72. The business has a fifty day moving average price of $19.29 and a 200 day moving average price of $22.36.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last issued its quarterly earnings data on Wednesday, November 1st. The company reported $0.31 earnings per share for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.06). The company had revenue of $5.37 billion for the quarter, compared to analysts’ expectations of $5.42 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 4.85% and a net margin of 2.30%. During the same quarter last year, the company earned $0.40 earnings per share. Equities research analysts expect that Fresenius Medical Care AG & Co. KGaA will post 1.25 EPS for the current fiscal year.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

Several institutional investors have recently bought and sold shares of FMS. Clear Street Markets LLC acquired a new stake in Fresenius Medical Care AG & Co. KGaA in the fourth quarter valued at approximately $28,000. Assetmark Inc. grew its holdings in Fresenius Medical Care AG & Co. KGaA by 61.1% in the first quarter. Assetmark Inc. now owns 1,969 shares of the company’s stock valued at $42,000 after purchasing an additional 747 shares during the period. JPMorgan Chase & Co. grew its holdings in Fresenius Medical Care AG & Co. KGaA by 34.7% in the fourth quarter. JPMorgan Chase & Co. now owns 3,432 shares of the company’s stock valued at $57,000 after purchasing an additional 885 shares during the period. Atlas Capital Advisors LLC acquired a new stake in Fresenius Medical Care AG & Co. KGaA in the second quarter valued at approximately $71,000. Finally, BNP Paribas Arbitrage SNC acquired a new stake in Fresenius Medical Care AG & Co. KGaA in the second quarter valued at approximately $120,000. 5.81% of the stock is owned by institutional investors and hedge funds.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.